Trials / Completed
CompletedNCT00035256
Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 330 (planned)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Female
- Age
- 55 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether the increase in spine bone mineral density that has been generally observed in previous clinical studies involving the study drug can be maintained or even increased if followed with raloxifene HCl. All qualifying study participants will receive the study drug followed by treatment with raloxifene HCl or placebo. All study participants will receive raloxifene HCl in the third phase of the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | teriparatide | |
| DRUG | raloxifene HCl | |
| DRUG | placebo |
Timeline
- Start date
- 2001-10-01
- Completion
- 2005-07-01
- First posted
- 2002-05-03
- Last updated
- 2007-05-15
Locations
5 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00035256. Inclusion in this directory is not an endorsement.